Anhui Anke BioTech Group (300009) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.055x

Based on the latest financial reports, Anhui Anke BioTech Group (300009) has a cash flow conversion efficiency ratio of 0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥240.51 Million ≈ $35.19 Million USD) by net assets (CN¥4.34 Billion ≈ $635.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300009 equity to assets ratio to measure how much of total assets are equity-financed.

Anhui Anke BioTech Group - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Anhui Anke BioTech Group's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Anhui Anke BioTech Group (300009) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Anhui Anke BioTech Group Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Anhui Anke BioTech Group ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Ningxia Jiaze Renewables Corp
SHG:601619
0.189x
Far Eastern International Bank
TW:2845
-0.049x
Western Union Co
NYSE:WU
0.120x
Entra ASA
OL:ENTRA
0.054x
VusionGroup
PA:VU
1.509x
STROEER (UNSP.ARD)/4/1
F:SAXB
0.231x
Gansu Jingyuan Coal Industry and Electricity Power Co Ltd
SHE:000552
0.029x
Batu Kawan Bhd
KLSE:1899
-0.060x

Annual Cash Flow Conversion Efficiency for Anhui Anke BioTech Group (2006–2024)

The table below shows the annual cash flow conversion efficiency of Anhui Anke BioTech Group from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Anhui Anke BioTech Group market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥4.30 Billion
≈ $629.22 Million
CN¥685.37 Million
≈ $100.29 Million
0.159x -36.37%
2023-12-31 CN¥3.93 Billion
≈ $575.42 Million
CN¥985.01 Million
≈ $144.14 Million
0.250x +21.91%
2022-12-31 CN¥3.40 Billion
≈ $497.78 Million
CN¥698.98 Million
≈ $102.28 Million
0.205x +0.75%
2021-12-31 CN¥2.90 Billion
≈ $424.88 Million
CN¥592.17 Million
≈ $86.65 Million
0.204x +28.50%
2020-12-31 CN¥2.93 Billion
≈ $428.54 Million
CN¥464.80 Million
≈ $68.01 Million
0.159x +44.95%
2019-12-31 CN¥2.70 Billion
≈ $395.10 Million
CN¥295.63 Million
≈ $43.26 Million
0.109x -23.41%
2018-12-31 CN¥2.01 Billion
≈ $294.29 Million
CN¥287.49 Million
≈ $42.07 Million
0.143x -10.32%
2017-12-31 CN¥1.76 Billion
≈ $257.60 Million
CN¥280.63 Million
≈ $41.06 Million
0.159x -11.88%
2016-12-31 CN¥1.43 Billion
≈ $208.70 Million
CN¥258.01 Million
≈ $37.75 Million
0.181x +92.66%
2015-12-31 CN¥1.26 Billion
≈ $185.03 Million
CN¥118.73 Million
≈ $17.37 Million
0.094x -33.17%
2014-12-31 CN¥773.47 Million
≈ $113.18 Million
CN¥108.68 Million
≈ $15.90 Million
0.141x +74.44%
2013-12-31 CN¥660.60 Million
≈ $96.67 Million
CN¥53.21 Million
≈ $7.79 Million
0.081x -13.16%
2012-12-31 CN¥580.03 Million
≈ $84.88 Million
CN¥53.80 Million
≈ $7.87 Million
0.093x +602.56%
2011-12-31 CN¥543.88 Million
≈ $79.59 Million
CN¥7.18 Million
≈ $1.05 Million
0.013x -85.46%
2010-12-31 CN¥522.30 Million
≈ $76.43 Million
CN¥47.43 Million
≈ $6.94 Million
0.091x +16.32%
2009-12-31 CN¥495.41 Million
≈ $72.49 Million
CN¥38.67 Million
≈ $5.66 Million
0.078x -55.44%
2008-12-31 CN¥148.64 Million
≈ $21.75 Million
CN¥26.04 Million
≈ $3.81 Million
0.175x -31.56%
2007-12-31 CN¥137.09 Million
≈ $20.06 Million
CN¥35.10 Million
≈ $5.14 Million
0.256x +5.30%
2006-12-31 CN¥122.00 Million
≈ $17.85 Million
CN¥29.66 Million
≈ $4.34 Million
0.243x --

About Anhui Anke BioTech Group

SHE:300009 China Biotechnology
Market Cap
$2.04 Billion
CN¥13.97 Billion CNY
Market Cap Rank
#6028 Global
#1138 in China
Share Price
CN¥8.36
Change (1 day)
+1.21%
52-Week Range
CN¥7.50 - CN¥12.30
All Time High
CN¥127.71
About

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterf… Read more